Company

Luxa Biotechnology LLC

Pharmaceutical Manufacturing The Critical Unmet Needs in Dry Amd. We’d Love to See You There—stay Tuned for More Updates as We Continue Pushing the Boundaries of Transformative Treatments! 6 employees

Employees: 6

www.neuralsci.org LinkedIn Crunchbase

Luxa Biotechnology LLC Overview

Headquarters: The Critical Unmet Needs in Dry Amd. We’d Love to See You There—stay Tuned for More Updates as We Continue Pushing the Boundaries of Transformative Treatments!
Website: www.neuralsci.org
Industry: Pharmaceutical Manufacturing
Employees: 6
Funding: 4.0M
NAICS: Pharmaceutical and Medicine Manufacturing

Medicinal and Botanical Manufacturing

Pharmaceutical Preparation Manufacturing

Keywords

Albany

About Luxa Biotechnology LLC

Luxa Biotechnology (LuxaBio) is a clinical-stage biotechnology company developing a novel adult RPE stem cell (RPESC) therapy for dry AMD. The proprietary adult RPESC-derived RPE stem cell product was developed at and licensed from the NSCI. LuxaBio is a partnership between the NSCI research institute and Y2 Solution, a Korean company to evaluate RPESC in a clinical trial to test the safety and efficacy of RPE progenitor stage progeny as a potential therapy for dry AMD. LuxaBio maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. The Phase 1/2a clinical trial of RPESC-RPE-4W for the Treatment of Dry Age-related Macular Degeneration includes the Cedars Sinai Biomanufacturing Center, Emmes, the University of Michigan Kellogg Eye Center, the National Eye Institute.